ClinicalTrials.gg
CompletedNCT00109707Updated Jun 29, 2021Results posted

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

A Phase 1/2 interventional study of Nilotinib in Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) and Hypereosinophilic Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 101 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
507
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
3rd of 66
507 · median 55
Started
2005
with 3 others
Phase 1/2
6 of 66
none open now
Registered
2nd of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 3rd largest by enrollment, is one of 4 that started in 2005, is one of 6 in phase 1/2, and was the 2nd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions:

Relapsed/refractory Ph+ Acute lymphoblastic leukemia (ALL) (arm 1)

Group A - Imatinib failure only (arms 2, 3 and 4)

  • imatinib-resistant or intolerant CML - Chronic Phase (CP)
  • imatinib-resistant or intolerant CML - Accelerated Phase (AP)
  • imatinib-resistant or intolerant CML - Blast Crisis (BC)

Group B - Imatinib and other TKI failure (arms 2, 3 and 4)

  • imatinib-resistant or intolerant CML - Chronic Phase (CP)
  • imatinib-resistant or intolerant CML - Accelerated Phase (AP)
  • imatinib-resistant or intolerant CML - Blast Crisis (BC)

Hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) (arm 5)

Systemic mastocytosis (Sm) (arm 6)

03

Conditions studied

  • Chronic Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
  • Hypereosinophilic Syndrome
  • Systemic Mastocytosis

Keywords

  • CML in blast crisis
  • CML in chronic phase
  • CML in accelerated phase
  • Gleevec resistance
  • Gleevec intolerant
  • Gleevec and CML
  • imatinib resistance
  • imatinib intolerant
  • Hypereosinophilic Syndrome
  • Systemic Mastocytosis
  • Chronic eosinophilic syndrome
  • Philadelphia chromosome positive acute lymphoblastic leukemia
  • HES
  • CEL
  • CML
  • SM
  • Ph+ ALL refractory to standard therapy
  • Ph+ALL relapsed
  • AMN107A
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main inclusion criteria include:

  • Patients with CML in blast crisis, CML in accelerated phase defined as never in blast crisis phase, or CML in chronic phase defined as never been in blast crisis phase or accelerated phase who have: *developed progressive disease during therapy with at least 600 mg of imatinib per day, -OR- *patients with CML on imatinib therapy, at any dose, developing progressive disease and the presence of a genetic mutation likely to result in imatinib resistance -OR- *have developed an intolerance to imatinib
  • Ph+ ALL
  • Hypereosinophilic syndrome/chronic eosinophilic leukemia.
  • Systemic mastocytosis who have a clinical indication for treatment.
  • Prior imatinib therapy for patients with Ph+ ALL, HES/CEL and SM is permitted but is not required
  • CML patients who have been treated with an tyrosine kinase inhibitor who otherwise meet the definition of imatinib-resistance or intolerance are eligible
  • Written prior to any study procedures being performed

Exclusion criteria

Exclusion Criteria:

  • Impaired cardiac function
  • Patients with severe/chronic or uncontrolled medical conditions (including but not limited to diabetes, infections, GI impairment, CNS infiltration, liver and kidney disease)
  • Prior and concomitant use of certain medications (including but not limited to warfarin, chemotherapy, hematopoietic colony-stimulating growth factors, medications that can affect test results, other drugs )
  • Women who are pregnant or breastfeeding
  • Patients with a history of another primary that is currently or currently requires active intervention.
  • Patients unwilling to comply with the protocol.
  • Known diagnosis of (HIV) infection

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    CML-CP With Prior Imatinib Only

    Imatinib-resistant / intolerant PH+ CML-CP patients

    Drug: Nilotinib

  • Experimental
    CML-AP With Prior Imatinib Onl

    Imatinib-resistant / intolerant PH+ CML-AP patients

    Drug: Nilotinib

  • Experimental
    CML-CP

    Imatinib-resistant / intolerant PH+ CML-CP patients

    Drug: Nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Major Cytogenetic Response (MCyR)

    Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

  2. Number of Participants Confirmed Overall Hematological Response (Phase II)

    Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver). Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

Secondary outcomes

  1. Number of Participants With Overall Major Cytogenetic Responses (Phase II)

    Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and \>0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

  2. Number of Participants With Complete Hematologic Response (Phase II)

    A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; \< 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

  3. Participants With (MMR) Major Molecular Response (Phase II)

    MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

  4. Time to Progression (TTP) (Phase II)

    Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death. Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

  5. Overall Survival (OS) (Phase II)

    OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.

    Time frame: Up to End of the Treatment (Approximately 7.5 years)

  6. Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety

    Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.

    Time frame: From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years)

07

Results

Posted Jun 29, 2021

Participant flow

The study was conducted at 100 centers in 22 countries.

Participant flow — Overall Study
MilestoneCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
Started32113749
Entered extension study1061515
Completed6788
Not completed25412941
Withdrew: Discontinued in core study without entering the extension study21512234
Withdrew: Abnormal laboratory values100
Withdrew: Administrative problems201
Withdrew: Adverse event1023
Withdrew: Death400
Withdrew: Disease progression1243
Withdrew: Lost to follow-up300
Withdrew: Protocol violation100
Withdrew: Patient withdrew consent610

Outcome measures

PrimaryNumber of Participants With Major Cytogenetic Response (MCyR)

Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Major Cytogenetic Response (MCyR)
ParticipantsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
Number of Participants With Major Cytogenetic Response (MCyR)1914422
PrimaryNumber of Participants Confirmed Overall Hematological Response (Phase II)

Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver). Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Count of participants · Participants
Number of Participants Confirmed Overall Hematological Response (Phase II)
ParticipantsCML-AP With Prior Imatinib Only
Number of Participants Confirmed Overall Hematological Response (Phase II)76
SecondaryNumber of Participants With Overall Major Cytogenetic Responses (Phase II)

Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and \>0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Number · participants
Number of Participants With Overall Major Cytogenetic Responses (Phase II)
participantsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
Number of Participants With Overall Major Cytogenetic Responses (Phase II)1914422
SecondaryNumber of Participants With Complete Hematologic Response (Phase II)

A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; \< 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Number · participants
Number of Participants With Complete Hematologic Response (Phase II)
participantsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
Number of Participants With Complete Hematologic Response (Phase II)1587627
SecondaryParticipants With (MMR) Major Molecular Response (Phase II)

MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Count of participants · Participants
Participants With (MMR) Major Molecular Response (Phase II)
ParticipantsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib Only
Participants With (MMR) Major Molecular Response (Phase II)10618
SecondaryTime to Progression (TTP) (Phase II)

Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death. Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Median · Months
Time to Progression (TTP) (Phase II)
MonthsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib Only
Time to Progression (TTP) (Phase II)55.6 (0.1 to 77.8)15.9 (0.1 to 75.7)
SecondaryOverall Survival (OS) (Phase II)

OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.

Time frame:
Up to End of the Treatment (Approximately 7.5 years)
Reported as:
Median · months
Overall Survival (OS) (Phase II)
monthsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
Overall Survival (OS) (Phase II)NA (77.93 to NA)47.54 (38.24 to 64.30)NA (NA to NA)
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety

Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.

Time frame:
From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety
ParticipantsCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
Serious Adverse Events61265
Adverse Events57177

Adverse events

Collected over From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CML-CP With Prior Imatinib Only13/321 (4%)146/321 (45.5%)319/321 (99.4%)
CML-AP With Prior Imatinib Only14/137 (10.2%)55/137 (40.1%)136/137 (99.3%)
CML-CP0/49 (0%)21/49 (42.9%)48/49 (98%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
CoughRespiratory, thoracic and mediastinal disorders0/3210/1375/49
PneumoniaInfections and infestations2/3217/1374/49
ThrombocytopeniaBlood and lymphatic system disorders11/32111/1373/49
AnaemiaBlood and lymphatic system disorders4/3213/1373/49
NeutropeniaBlood and lymphatic system disorders7/3218/1370/49
PyrexiaGeneral disorders9/3216/1372/49
Febrile neutropeniaBlood and lymphatic system disorders4/3213/1372/49
White blood cell count increasedInvestigations0/3213/1372/49
Angina pectorisCardiac disorders12/3210/1370/49
Myocardial infarctionCardiac disorders7/3215/1370/49
Most frequent other events
Showing 10 of 98
Most frequent other events
EventCML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CP
AnaemiaBlood and lymphatic system disorders71/32161/1379/49
ThrombocytopeniaBlood and lymphatic system disorders107/32160/13716/49
RashSkin and subcutaneous tissue disorders118/32139/13720/49
NauseaGastrointestinal disorders121/32141/13713/49
PyrexiaGeneral disorders66/32149/1378/49
HeadacheNervous system disorders114/3210/13711/49
FatigueGeneral disorders105/32128/13713/49
PruritusSkin and subcutaneous tissue disorders104/32118/1379/49
NeutropeniaBlood and lymphatic system disorders57/32139/13715/49
DiarrhoeaGastrointestinal disorders93/32134/1376/49

Baseline characteristics

Age, Customized
Age, Customized(Participants)CML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CPTotal
<35 years228333
≥35 to <55 years1044916169
≥55 to <65 years973912148
≥65 years984118157
Sex: Female, Male
Sex: Female, Male(Participants)CML-CP With Prior Imatinib OnlyCML-AP With Prior Imatinib OnlyCML-CPTotal
Female1596125245
Male1627624262
08

Study locations

101 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford University Medical Center
    Stanford, California 94305-5750, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • H. Lee Moffitt Cancer Center & Research Institute Dept.of H. Lee Moffitt
    Tampa, Florida 33612, United States
  • University of Chicago Medical Center Dept. of U. of Chicago Hosp(3)
    Chicago, Illinois 60637, United States
  • University of Illinois at Chicago Divisionof Hematology/Oncology
    Chicago, Illinois, United States
  • Indiana Blood and Marrow Institute Dept of Indiana Blood&Mar (2)
    Beech Grove, Indiana 46107, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Div.of Hematologic Malignancie
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Michigan Health System Clinical Trials Office
    Ann Arbor, Michigan 48109, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute Rosewell SC
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10017, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • The Jones Clinic
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center, Clinical Trials Center Investigational Drug Services
    Nashville, Tennessee 37212, United States
  • MD Anderson Cancer Center/University of Texas
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Novartis Investigative Site
    St. Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Prahran, Victoria 3181, Australia
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Haine-saint-Paul, 7100, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Yvoir, 5530, Belgium
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E3, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 1A1, Canada
  • Novartis Investigative Site
    Vejle, DK-7100, Denmark
  • Novartis Investigative Site
    HUS Helsinki, FIN-00029, Finland
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Dijon, 21034, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Limoges cedex, 87042, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Rennes, 35019, France
  • Novartis Investigative Site
    Vandoeuvre les Nancy, 54511, France
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Frankfurt/M, 60590, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Mannheim, 68169, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Pokfulam, Hong Kong
  • Novartis Investigative Site
    Bergamo, BG 24128, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Monza, MB 20900, Italy
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Pescara, PE 65124, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Reggio Calabria, RC 89124, Italy
  • Novartis Investigative Site
    Roma, RM 00144, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Hwasun-gun, Jeollanam-do 519-809, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 137-701, Korea, Republic of
  • Novartis Investigative Site
    Taegu, 700 - 721, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Rotterdam, Netherlands
  • Novartis Investigative Site
    Grafton, Auckland, New Zealand
  • Novartis Investigative Site
    Oslo, NO-0310, Norway
  • Novartis Investigative Site
    Katowice, 40-635, Poland
  • Novartis Investigative Site
    Lodz, 90-153, Poland
  • Novartis Investigative Site
    Warszawa, 02-097, Poland
  • Novartis Investigative Site
    Warszawa, 02-776, Poland
  • Novartis Investigative Site
    Wroclaw, 50-367, Poland
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Hospitalet de LLobregat, Catalunya 08907, Spain
  • Novartis Investigative Site
    Göteborg, SE-413 45, Sweden
  • Novartis Investigative Site
    Linköping, SE-581 85, Sweden
  • Novartis Investigative Site
    Lund, SE-221 85, Sweden
  • Novartis Investigative Site
    Uppsala, SE-751 85, Sweden
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Genève, 1211, Switzerland
  • Novartis Investigative Site
    Niaosong Township, 83301, Taiwan
  • Novartis Investigative Site
    Birmingham, B15 2TH, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB2 2QQ, United Kingdom
  • Novartis Investigative Site
    Glasgow - Scotland, G12 OYN, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    London, W12 0NN, United Kingdom

Showing the first 100 of 101 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, Muller MC, Reiter A, Santanastasio H, Leung M, Novick S, Kantarjian HM. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015 Nov;141(11):2047-60. doi: 10.1007/s00432-015-1988-0. Epub 2015 May 23. PubMed 26002753 ↗
  • Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. doi: 10.1007/s00432-013-1529-7. Epub 2013 Sep 22. PubMed 24057647 ↗
  • Stein AM, Martinelli G, Hughes TP, Muller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173. PubMed 23547655 ↗
  • Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27;117(4):1141-5. doi: 10.1182/blood-2010-03-277152. Epub 2010 Nov 22. PubMed 21098399 ↗
  • Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22. PubMed 17715389 ↗
  • Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. doi: 10.1056/NEJMoa055104. PubMed 16775235 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2005 to primary completion in Sep 2012, 89 months.

Results were first posted in Jun 2021, 8 years 9 months after primary completion.

Of 26 phase 1/2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 94. This study's 89 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2005
First posted
May 3, 2005
StartActual
Apr 2005
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Jun 29, 2021
Last update
Jun 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00109707
Responsible party
Sponsor
First posted
May 3, 2005
Start date
Apr 2005
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Jun 29, 2021
Last update
Jun 29, 2021

Study contacts

Novartis Pharmaceuticlas
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion